← All trials
NCT01914081
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2018
- Primary completion
- Nov 30, 2019
- Completion date
- Nov 30, 2020
- First posted
- Aug 1, 2013
- Last posted
- Nov 14, 2018
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ManitobaLead sponsor
- Agriculture and Agri-Food CanadaCollaborator
- Manitoba Medical Service FoundationCollaborator
- University of ManitobaOverall official - principal investigator
- University of ManitobaReponsible party - principal investigator
- University of ManitobaOfficial
- University of ManitobaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.